peoplePerson
Nancy U. Lin
Nancy Lin is the leading authority on brain metastases from breast cancer, including the HER2CLIMB tucatinib data in patients with active brain disease.
Directs the metastatic breast cancer programme; led HER2CLIMB analyses of tucatinib in brain metastases and defines CNS response criteria (RANO-BM) used across trials.
Role
Director, Metastatic Breast Cancer Program; Associate Chief, Division of Breast Oncology
Institution
Specialisms
Breast cancer brain metastasesHER2-positive breast cancerCNS pharmacology
Profiles
| Title | Journal | Year |
|---|---|---|
| Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial | Journal of Clinical Oncology | 2020 |